Gastrointestinal Cancer Clinical Trials & Research at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following gastrointestinal cancer clinical trials:

Gastric Cancer
Colorectal Cancer


Gastric

A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy (BeiGene)

Phase III

The purpose of this study is to compare the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced or inoperable gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Patients must have achieved a partial response that is maintained for ≥ 4 weeks or a complete response with platinum-based first-line chemotherapy.

Treatment agent: BGB-290 (PARPi)
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03427814


Colorectal

A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer (POLAR)

Phase III

This is a multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by oxaliplatin. Patients with metastatic colorectal cancer (CRC), who are indicated for first-line modified FOLFOX-6 (mFOLFOX6) chemotherapy for at least 3 months, without any pre-planned treatment breaks, will be randomized in a 1:1:1 ratio to one of three treatment arms: PledOx (2 μmol/kg) + mFOLFOX6 chemotherapy; PledOx (5 μmol/kg) + mFOLFOX6 chemotherapy; Placebo + mFOLFOX6 chemotherapy. The addition of an appropriate biologic therapy will be left to the discretion of the Investigator.

Treatment agent: mFOLFOX6 + PledOX vs mFOLFOX6 + placebo
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT03654729

Our Locations